AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 152 filers reported holding AKERO THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 1.85 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,875,086 | +28.8% | 76,613 | +18.9% | 0.00% | 0.0% |
| Q2 2023 | $3,008,237 | +36.4% | 64,430 | +11.7% | 0.00% | +100.0% |
| Q1 2023 | $2,205,995 | -26.2% | 57,658 | +4.4% | 0.00% | -50.0% |
| Q4 2022 | $2,987,594 | +292.4% | 55,243 | +131.9% | 0.00% | +100.0% |
| Q3 2022 | $761,440 | +545.4% | 23,826 | +90.9% | 0.00% | – |
| Q2 2022 | $117,974 | -28.5% | 12,484 | +7.4% | 0.00% | – |
| Q1 2022 | $164,902 | -45.4% | 11,621 | -18.0% | 0.00% | – |
| Q4 2021 | $302,000 | -5.9% | 14,169 | -1.5% | 0.00% | – |
| Q3 2021 | $321,000 | -15.3% | 14,382 | -5.8% | 0.00% | – |
| Q2 2021 | $379,000 | +53.4% | 15,260 | +78.9% | 0.00% | – |
| Q1 2021 | $247,000 | +8.3% | 8,529 | -3.3% | 0.00% | – |
| Q4 2020 | $228,000 | -6.6% | 8,824 | +11.5% | 0.00% | – |
| Q3 2020 | $244,000 | – | 7,917 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
| Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
| Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
| COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
| Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
| Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
| Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
| Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |